Top Markets
#1 Siacoin Siacoin +16.51%
#2 Seeker Seeker +13.30%
#3 Cash Cat Cash Cat +12.44%
#4 DogBull DogBull +9.95%
#5 0G 0G +9.07%
#6 Useless Coin Useless Coin +5.74%
#7 StonkBroker StonkBroker +4.63%
#8 The Black Bull The Black Bull +4.56%
#9 Akedo Akedo +4.31%
#10 Story Story +4.27%
Coin of the day
Siacoin Siacoin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
EirGenix Inc. EirGenix Inc.

EirGenix Inc.

6589
Classifica tra le azioni #14109
EirGenix Inc., founded in 2012 and based in New Taipei City, Taiwan, functions... EirGenix Inc., founded in 2012 and based in New Taipei City, Taiwan, functions as a contract development and manufacturing organization (CDMO) with operations spanning both domestic and international markets. The company offers a comprehensive range of services, encompassing cell line creation, process optimization, analytical testing and quality control, and current Good Manufacturing Practice (cGMP) compliant production utilizing both mammalian and microbial expression systems. They also specialize in services related to antibody-drug conjugates (ADCs). Beyond its service offerings, EirGenix is actively engaged in developing several therapeutic candidates. This pipeline includes EG12014/EGI014, a Trastuzumab biosimilar intended for cancer therapy, which has reached the biologics license application (BLA) submission stage. Other oncology-focused developments are EG1206A, a Pertuzumab biosimilar currently in Phase I clinical trials; EG13074, in preclinical development; and TSY0110(EG12043), an antibody-drug conjugate also in preclinical stages. Additionally, the company is advancing EG12021, a Bevacizumab biosimilar for cancer treatment, and EG62054, another biosimilar, both in preclinical development. In addition to its core activities, EirGenix manufactures and distributes a rapid antigen test for COVID-19, as well as the CRM197 carrier protein under the designation EG74032.
Prezzo delle azioni
$1.46
Ultima sincronizzazione: 2026-07-28
Capitalizzazione di mercato
$435.25M
Variazione (1 giorno)
-2.34%
Variazione (1 anno)
-25.65%
Paese
TW
Scambia EirGenix Inc. (6589)

Categoria

Healthcare
Ricavi di EirGenix Inc. (6589)
Ricavi nel Sep 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di EirGenix Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per EirGenix Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH